{"title":"美国国立卫生研究院研究机构间接费率上限-法律和政策","authors":"Lawrence O. Gostin, Jennifer S. Bard","doi":"10.1001/jama.2025.6238","DOIUrl":null,"url":null,"abstract":"This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.","PeriodicalId":518009,"journal":{"name":"JAMA","volume":"114 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The National Institutes of Health Cap on Indirect Rates for Research Institutions—Law and Policy\",\"authors\":\"Lawrence O. Gostin, Jennifer S. Bard\",\"doi\":\"10.1001/jama.2025.6238\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.\",\"PeriodicalId\":518009,\"journal\":{\"name\":\"JAMA\",\"volume\":\"114 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAMA\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1001/jama.2025.6238\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/jama.2025.6238","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The National Institutes of Health Cap on Indirect Rates for Research Institutions—Law and Policy
This Viewpoint examines the National Institutes of Health’s 15% uniform cap on indirect cost reimbursements for all federally funded biomedical research and the litigation that followed from a coalition of 22 states.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
